Drug Trial Radar · NCT04675333
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
172
Actual
Start
May 10, 2021
Primary completion
Mar 3, 2025
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- ALX Oncology Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Dec 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
Conditions
- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma
Interventions
evorpaceptDrug
IV Q3W
pembrolizumabDrug
IV Q3W
Cisplatin/Carboplatin; 5FUDrug
IV Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate per RECIST 1.1Time frame: Last randomized patient reaching at least 24 weeks of follow-up
Locations
44 sites in 8 countries. Site status is shown where the registry gives one.
Hoag Hospital
Irvine, California
University of California San Diego
La Jolla, California
Cedar Sinai Medical Center
Los Angeles, California
University of Miami, Sylvester Comprehensive Cancer Center
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
Rush University Medical Center
Chicago, Illinois
University of Louisville
Louisville, Kentucky
University of Maryland Medical System
Baltimore, Maryland
Memorial Sloan Kettering
New York, New York
The Ohio State University
Columbus, Ohio
Oregon Health & Science University/ Knight Cancer Institute
Portland, Oregon
Vanderbilt - Ingram Cancer Center
Nashville, Tennessee
Houston Methodist Cancer Center
Houston, Texas
Sir Charles Gairdner Hospital
Nedlands, Australia
Royal Brisbane and Womens Hospital
Herston, Queensland, Australia
Ashford Cancer Centre
Adelaide, South Australia, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
AZ Groeninge
Kortrijk, Belgium
Amsterdam UMC, Locatie VUMC
Amsterdam, Netherlands
Universitair Medisch Centrum Groningen
Groningen, Netherlands
National University Cancer Institute
Singapore, Singapore
National Cancer Centre Singapore
Singapore, Singapore
Chungbuk National University Hospital
Cheongju-si, South Korea
Yeungnam University Medical Center
Daegu, South Korea
Gachon University (GCU) - Gil Medical Center (Gil Hospital)
Incheon, South Korea
Seoul National University, Bundang Hospital
Seongnam, South Korea
CHA University - Bundang CHA General Hospital (CHA Bundang Medical Center)
Seongnam-si, South Korea
The Catholic University of Korea - Eunpyeong St. Mary's Hospital
Seoul, South Korea
Seoul National University Hospital (SNUH) - SMG-SNU Boramae Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Institut Catala d Oncologia (ICO)
Badalona, Spain
Institut Catala dOncologia
L'Hospitalet de Llobregat, Spain
Hospital Universitario Severo Ochoa
Leganés, Spain
Grupo Hospital de Madrid (HM) - Hospital Universitario Madrid Sanchinarro - Cent
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Regional Universitario de Malaga
Málaga, Spain
Hospital Universitario de Navarra
Pamplona, Spain
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.